ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO160

Efficacy and Side Effects of Denosumab for Stage 3b-4 CKD Patients with Osteoporosis: An Open-Label, Prospective Pilot Clinical Study

Session Information

Category: Bone and Mineral Metabolism

  • 502 Bone and Mineral Metabolism: Clinical


  • Lee, So-young, Eulji University College of Medicine, Seoul, Nowon, Korea (the Republic of)

We sought to evaluate the efficacy and safety of denosumab, including denosumab-induced hypoglycemia, in patients with chronic kidney disease (CKD) stage 3b-4 and osteoporosis. We also aimed to evaluate whether denosumab affects coronary artery calcium score (CAC) in these patients.


A total of 27 female patients with CKD stage 3b-4 and osteoporosis were enrolled. Twenty patients received denosumab plus calcium carbonate and vitamin D, and 7 control patients received calcium carbonate and vitamin D for 1 year. Osteoporosis was confirmed by using dual-energy X-ray absorptiometry (DXA). Coronary multi-detector CT was performed to calculate the coronary calcium score.


No significant differences were found in medication history, demographics, eGFR, BMI, lumbar and hip BMD, bone turnover markers, 25(OH)D, homocysteine, CAC between the two groups at baseline. There was significant improvement of BMD in the denosumab treatment group. Lumbar spine, femur neck, total hip T score increased by 5.6±5.9%, 3.6±3.2%, 3.4±3.8% respectively, from baseline in the denosumab-treated group, while, 2.7±3.9%, -0.7±4.4%, -1.9±2.1% changes were observed in the control group. (Lumbar; P=0.273, femur neck; P=0.033, total hip; P=0.001). Among bone turnover markers, the percent change in bone ALP and CTX was -31.1±30.0% and -49.2±29.9% in the denosumab treatment group and -4.5±32.0% and -17.7±28.0% in the control group (ALP; P=0.027 and CTX; P=0.025). PTH level change were not different between two groups (denosumab; 9.0±81.7% vs. control; -0.7±79.4%, p=0.580). There were no significant changes in calcium, ionized calcium, phosphorus, and PTH levels throughout the study. CAC, and homocysteine percent change did not differ between groups (CAC; P=0.563 and homocysteine; P=0.143)


Denosumab has provided significant benefits without hypocalcemia for 1 year in patients with stage 3b-4 CKD when used judiciously. However, denosumab treatment did not affect homocysteine and CAC in these patients.


  • Private Foundation Support